

U.S. Patent Application No. 10/628,322  
Preliminary Amendment dated April 7, 2004

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claim 1. (currently amended): A method of treating ~~or retarding~~ a malignant tumor in a mammal comprising administering orally ~~subcutaneously~~ to said mammal in need of such treatment an effective amount of a water-insoluble camptothecin compound with a closed-lactone ring at a dose lower than 1.5 mg/Kg/day, wherein said malignant tumor is selected from the group consisting of ~~breast cancer, colon cancer, lung cancer, stomach cancer, ovarian cancer, pancreas cancer, prostate cancer, osteosarcoma, melanoma, and bladder cancer;~~

and wherein said compound is selected from the group consisting of 20(S)-camptothecin, 9-nitro-20(S)-camptothecin, 9-amino-20(s)-camptothecin, dimethylaminomethyl-10-hydroxy-20(S)-camptothecin (topotecan), 7-ethyl-10-carbonyloxy-camptothecin (camptothecin-11), 7-ethyl-10-hydroxy-20(S)-camptothecin, 10,11-methylenedioxy-20(S)-camptothecin, 9-chloro-20(S)-camptothecin, 9-bromo-20(S)-camptothecin, 9-hydroxy-20(S)-camptothecin, 11-hydroxy-20(S)-camptothecin, 10-hydroxy-20(S)-camptothecin, and mixtures thereof.

Claim 2. (canceled)

Claim 3. (canceled)

Claim 4. (currently amended): The method of according to claim 1, wherein said camptothecin compound effective amount is administered to the mammal at a dose of from about 0.75 daily from about .75 mg/per kg to about 1.5 mg/Kg/day mg/per kg in mice.

Claim 5. (canceled)

Claim 6. (canceled)

U.S. Patent Application No. 10/628,322  
Preliminary Amendment dated April 7, 2004

Claim 7. (currently amended): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin.

Claim 8. (currently amended): The method of claim 1, wherein said camptothecin compound is 9-amino-20(S)-camptothecin.

Claim 9. (currently amended): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is breast cancer.

Claim 10. (new): The method of claim 1, wherein the malignant tumor is breast cancer, colon cancer, lung cancer, stomach cancer, ovarian cancer, pancreas cancer, prostate cancer, osteosarcoma, melanoma, or bladder cancer.

Claim 11. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is colon cancer.

Claim 12. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is lung cancer.

Claim 13. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is pancreatic cancer.

Claim 14. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is malignant melanoma.

Claim 15. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is stomach cancer.

Claim 16. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is ovarian cancer.

Claim 17. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor prostate cancer.

U.S. Patent Application No. 10/628,322  
Preliminary Amendment dated April 7, 2004

Claim 18. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is osteosarcoma.

Claim 19. (new): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is bladder cancer.